MEDP
Medpace Holdings·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
High Cash/net Profit Ratio
EPS Beats Expectation
RSI Oversold
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MEDP
Medpace Holdings, Inc.
A global full-service clinical contract research organization that provides Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries
Life Science Tools and Services
02/18/2014
08/11/2016
NASDAQ Stock Exchange
5,900
12-31
Common stock
5375 Medpace Way, Cincinnati, OH 45227
--
Medpace Holdings, Inc., a Delaware corporation, was incorporated on February 18, 2014. The company is one of the world's leading clinical contract research organizations by revenue, focusing on providing science-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The company's mission is to accelerate the global development of safe and effective medical therapies. The company differentiates itself from its competitors through a rigorous operating model centered on providing full-service phase I-IV clinical development services and therapeutic expertise.
Earnings Call
Q1/2025
Estimate EPS3.08
Actual EPS3.67
Estimate Revenue527.15M
Actual Revenue558.57M
Medpace's Q1 2025 Earnings Call: Navigating Contradictions in Business Environment, Cancellation Rates, and Book-to-Bill Expectations
Apr 23,2025 09:44
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
MEDP has released its 2025 Q3 earnings. EPS was reported at 3.86, versus the expected 3.57, beating expectations. The chart below visualizes how MEDP has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MEDP has released its 2025 Q3 earnings report, with revenue of 659.90M, reflecting a YoY change of 23.74%, and net profit of 111.14M, showing a YoY change of 15.25%. The Sankey diagram below clearly presents MEDP's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
